TITLE

KETAMINE, AN NMDA RECEPTOR ANTAGONIST PREVENTS THE INDUCTION OF CENTRAL SENSITISATION IN A HUMAN MODEL OF VISCERAL PAIN HYPERSENSITIVITY

AUTHOR(S)
Willert, R.P.; Hobson, A.R.; Woolf, C.J.; Thompson, D.G.; Aziz, Q.
PUB. DATE
April 2003
SOURCE
Gut;Apr2003 Supplement 1, Vol. 52, pA15
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Introduction: Recent studies indicate that proximal oesophageal (PO) pain hypersensitivity to distal oesophageal acid infusion occurs due to increased neuronal excitability, ie central sensitisation CS. In somatic tissues the induction of CS in the spinal cord is dependent on the N-methyI-D-aspartate (NMDA) receptor, however, the role of the NMDA receptor in mediating visceral hypersensitivity is unknown. Aim: To determine if the NMDA receptor antagonist ketamine attenuates CS in a model of human oesophageal hypersensitivity. Methods: 14 healthy subjects (7 male, age 18-43 years) were studied in a randomised two way double blind placebo controlled crossover study. Pain thresholds (PT) to electrical stimulation were determined in the PO and foot, and then either ketamine (0.075 mg/kg) or placebo (0.9% NaCI) was given as an intravenous bolus. A 30 min infusion of 0.15 M acid was then given in the distal oesophagus together with an intravenous infusion of ketamine 0.005 mg/kg) or placebo (0.9% NaCI) for 30 min. PT in the PO and foot were then repeatedly tested for 120 min post-infusion. PO pH and an attention task was performed throughout. Results: In all but one subject (excluded from analysis) the pH remained above 5 in the PO during each study. Ketamine attenuated the reduction in PT in the PO in response to acid in the distal oesophagus (Area under curve (AUC+ 16.9±3.9 and 12.3±2.6 for ketamine and placebo, respectively, p < 0.002). Ketamine did not affect PT in the foot compared with placebo (AUC 10.8±4.7 and 11.2±5.2, p = 0.5). Ketamine reduced attention scores during the infusion compared with baseline (Mean 54.4±2.6 and 46.1±4.6, respectively, p < 0.001) but this had ceased 30 min post-infusion (mean 54.9±2.8 and 54.4±2.6, p = 0.27). Conclusion: The attenuation of PO hypersensitivity by ketamine suggests that the NMDA receptor contributes to the generation of CS in visceral pain. Therefore, NMDA...
ACCESSION #
9747356

 

Related Articles

  • COMBATING CHRONIC FOOD ALLERGIES IN KIDS WITH A MULTIDISCIPLINARY APPROACH. Rothenbers, Marc; Collins, Dee // Cincinnati Magazine;Jan2011, Vol. 44 Issue 4, p66 

    The article offers the author's insights on eosinophilic gastroin testinal disorders (EGID), a chronic allergic reaction, wherein one of 1,000 children have eosinophilic esophagitis.

  • Correction: CaldendrinJacob: A Protein Liaison That Couples NMDA Receptor Signalling to the Nucleus. Dieterich, Daniela C.; Karpova, Anna; Mikhaylova, Marina; Zdobnova, Irina; König, Imbritt; Landwehr, Marco; Kreutz, Martin; Smalla, Karl-Heinz; Richter, Karin; Landgraf, Peter; Reissner, Carsten; Boeckers, Tobias M.; Zuschratter, Werner; Spilker, Christina; Seidenbecher, Constanze I; Garner, Craig C.; Gundelfinger, Eckart D.; Kreutz, Michael R. // PLoS Biology;Jan2009, Vol. 7 Issue 1, pe22 

    A correction to the article "Caldendrin-Jacob: A Protein Liaison That Couples NMDA Receptor Signalling to the Nucleus" that was published in the 2008 issue is presented.

  • Endogenous BDNF augments NMDA receptor phosphorylation in the spinal cord via PLCγ, PKC, and PI3K/Akt pathways during colitis. Miao Liu; Kay, Jarren C.; Shanwei Shen; Li-Ya Qiao // Journal of Neuroinflammation;Aug2015, Vol. 12 Issue 1, p1 

    Background: Spinal central sensitization is an important process in the generation and maintenance of visceral hypersensitivity. The release of brain-derived neurotrophic factor (BDNF) from the primary afferent neurons to the spinal cord contributes to spinal neuronal plasticity and increases...

  • Eosinophilic Esophagitis: A New and Rapidly Emerging Condition. Gaby, Alan R. // Townsend Letter;Jan2013, Issue 354, p110 

    The author discusses eosinophilic esophagitis (EE), an inflammatory disorder of the esophagus. Information is offered on its prevalence in Western societies, clinical manifestations in infants and adults, and medications in treating the condition. He explores hypotheses in the emergence of EE as...

  • N-acetylaspartylglutamate in Canavan disease: an adverse effector? Burlina, A. P.; Ferrari, V.; Divry, P.; Gradowska, W.; Jakobs, C.; Bennett, M. J.; Sewell, A. C.; Dionisi-Vici, C.; Burlina, A. B. // European Journal of Pediatrics;1999, Vol. 158 Issue 5, p406 

    Abstract We measured N-acetylaspartate and its precursor/product N-acetylaspartylglutamate (NAAG) in urine of patients with Canavan disease using capillary zone electrophoresis. Abnormal levels of NAAG were found in 32 of 43 patients examined. Elevated NAAG was also present in the CSF of one...

  • N-Methyl-D-Aspartate Receptor-Coupled GlycineB Receptors in the Pathogenesis and Treatment of Schizophrenia: A Critical Review. Millan, M.J. // Current Drug Targets - CNS & Neurological Disorders;Apr2002, Vol. 1 Issue 2, p191 

    Glutamatergic pathways, metabotropic receptors, and ionotropic a-amino-3-hydroxy-5-methylisoxazole-4-proprionic acid (AMPA), kainate and N-methyl-D-aspartate (NMDA) receptors are all implicated in the etiology and management of schizophrenia. As concerns NMDA receptors, open channel blockers...

  • EFFECT OF KETAMINE, DEXTROMETHORPHAN, AND MK-801 ON COCHLEAR DYSFUNCTION INDUCED BY TRANSIENT ISCHEMIA. Tabuchi, Keiji; Ito, Zenya; Tsuji, Shigeki; Hara, Akira; Wada, Tetsuro; Kusakari, Jun // Annals of Otology, Rhinology & Laryngology;Jan2002, Vol. 111 Issue 1, p44 

    Investigates the effects of N-methyl-D-aspartate (NMDA) against ischemia-reperfusion injury of the cochlea. Administration of NMDA receptor antagonism not to protect cochlea; Effectivity of NMDA; List of NMDA antagonist.

  • NR2B Selective NMDA Receptor Antagonists. Nikam, Sham S.; Meltzer, Leonard T. // Current Pharmaceutical Design;May2002, Vol. 8 Issue 10, p845 

    NR2B antagonists have received considerable attention in recent years. In this class of excitatory amino acid receptor antagonists NR2B antagonists have shown efficacy in neuroprotection, anti-hyperalgesic and anti-Parkinson animal models. Several groups are involved in developing these...

  • Ifenprodil, a Novel NMDA Receptor Antagonist : Site and Mechanism of Action. Williams, Keith // Current Drug Targets;Sep2001, Vol. 2 Issue 3, p285 

    Ifenprodil is a novel N-methyl-D-aspartate (NMDA) receptor antagonist that selectively inhibits receptors containing the NR2B subunit. As such, it has become widely used as a tool to study subtypes of NMDA receptors both in vitro and in vivo, and as a tool for molecular studies of the properties...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics